Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder.

Department of Psychiatry, Trakya University School of Medicine, 22030 Edirne, Turkey.
Psychopharmacology (Impact Factor: 3.99). 12/2003; 170(4):429-33. DOI: 10.1007/s00213-003-1566-z
Source: PubMed

ABSTRACT Over the last 15 years, an increasing body of evidence has suggested a causal relationship between depression and the immunological activation and hypersecretion of pro-inflammatory cytokines, such as interleukin-1, interleukin-6 and tumor necrosis factor-alpha (TNF-alpha). However, little is known about the probable relationship of serum TNF-alpha with major depressive disorder (MDD).
To assess whether serum TNF-alpha levels could be associated with the clinical course of MDD.
TNF-alpha and C-reactive protein (CRP) serum concentrations, erythrocyte sedimentation rate, and leukocyte count were measured in 26 MDD patients and in 17 controls. The measurements were repeated following 6 weeks of antidepressant treatment with selective serotonin re-uptake inhibitors. Psychopathological improvement and the severity of depression were evaluated with the Hamilton Depression Rating Scale (HAMD) and Beck Depression Inventory (BDI).
On admission, serum TNF-alpha and leukocyte count were significantly higher in MDD patients compared to controls ( P<0.001 and P=0.005, respectively). With the antidepressant treatment, both HAMD and BDI scores decreased significantly (P<0.001 for both). Comparison of pre- and post-treatment measurements revealed that TNF-alpha, CRP, and leukocyte count decreased to levels comparable with those of the control subjects ( P<0.001, P=0.01, and P=0.01, respectively).
The results emphasized that some immunological parameters, such as CRP, leukocyte count and TNF-alpha, are significantly involved in the clinical course and treatment response in MDD. TNF-alpha in particular could be considered as a potential state marker in MDD.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: During the past two decades, there has been increasing interest in understanding and characterizing the role of inflammation in major depressive disorder (MDD). Indeed, several are the evidences linking alterations in the inflammatory system to Major Depression, including the presence of elevated levels of pro-inflammatory cytokines, together with other mediators of inflammation. However, it is still not clear whether inflammation represents a cause or whether other factors related to depression result in these immunological effects. Regardless, exposure to early life stressful events, which represent a vulnerability factor for the development of psychiatric disorders, act through the modulation of inflammatory responses, but also of neuroplastic mechanisms over the entire life span. Indeed, early life stressful events can cause, possibly through epigenetic changes that persist over time, up to adulthood. Such alterations may concur to increase the vulnerability to develop psychopathologies. In this review we will discuss the role of inflammation and neuronal plasticity as relevant processes underlying depression development. Moreover, we will discuss the role of epigenetics in inducing alterations in inflammation-immune systems as well as dysfunction in neuronal plasticity, thus contributing to the long-lasting negative effects of stressful life events early in life and the consequent enhanced risk for depression. Finally we will provide an overview on the potential role of inflammatory system to aid diagnosis, predict treatment response, enhance treatment matching, and prevent the onset or relapse of Major Depression.
    Frontiers in Cellular Neuroscience 01/2015; 9:40. DOI:10.3389/fncel.2015.00040 · 4.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Major depressive disorder (MDD) is one of medicine’s most prevalent and costly disorders, and it has high rates of comorbidity with a wide range of infectious diseases and serious medical disorders. MDD has been linked to immunologic alterations that include suppressed cellular immune function, excessive inflammatory response, and greater susceptibility to infection. In this chapter, we review research on environmental factors and immune factors associated with depression including: a clinical overview of MDD, current evidence on environmental risk factors and alterations in immune function, and the role of immune factors in the etiology of depression. In a concluding section, we discuss an integrative hypothesis—The Infection-Defense Hypothesis—that may help to resolve an important psychiatric puzzle, offering an explanation for why immune function is related to depression, and why depression remains common, despite its high evolutionary costs and evidence for its significant heritability.
    Immunotoxicity, Immune Dysfunction, and Chronic Disease, Edited by Rodney Dietert, Robert Leubke, 04/2012: pages 345-385; Humana Press., ISBN: 978-1-61779-811-5
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The association between cholelithiasis and depression remains unclear. We examined the risk of depression in patients with cholelithiasis. From the National Health Insurance population claims data of Taiwan, we identified 14071 newly diagnosed cholelithiasis patients (4969 symptomatic and 9102 asymptomatic) from 2000 to 2010. For each cholelithiasis patient, 4 persons without cholelithiasis were randomly selected in the control cohort from the general population frequency matched by age, sex, and diagnosis year. Both cohorts were followed up until the end of 2011 to monitor the occurrence of depression. Adjusted hazard ratios (aHRs) of depression were estimated using the Cox proportional hazards model after controlling for age, sex and comorbidities. The overall incidence rates of depression were 1.87- and 1.83-fold greater in the symptomatic and asymptomatic cholelithiasis subcohorts than in the control cohort (incidence, 10.1 and 9.96 vs 5.43 per 1000 person-years, respectively). The multivariable Cox proportional hazards regression analysis revealed higher variable-specific aHRs in women than in men, in younger patients than in older patients, and in those without comorbidities than in those with any comorbidity. Cholecystectomy reduced the hazard of developing depression with aHRs of 0.79 (95% confidence interval [CI] 0.62–0.99) for symptomatic cholelithiasis patients and 0.76 (95% CI 0.60–0.96) for asymptomatic patients. Patients with cholelithiasis are at a higher risk of developing depression than the general population. Patients could be benefited from cholecystectomy and have the hazard of developing depression significantly reduced.
    Medicine 03/2015; 94(10):e631. DOI:10.1097/MD.0000000000000631 · 4.87 Impact Factor